In the FLOW trial, semaglutide reduced major kidney events by 24% and death by 20% across all severity levels of chronic kidney disease, with the sickest patients seeing the greatest mortality benefit.
53% lower death riskPatients with the most severe kidney damage (UACR ≥2000 mg/g) saw the largest benefit: a 53% reduction in all-cause death with semaglutide versus placebo
What the researchers found
In this subgroup analysis of the landmark FLOW trial (3,533 participants, median 3.4-year follow-up), once-weekly semaglutide 1 mg reduced the primary composite kidney outcome by 24% (HR 0.76, 95% CI 0.66-0.88) and all-cause death by 20% (HR 0.80, 95% CI 0.67-0.95) compared to placebo in people with type 2 diabetes and chronic kidney disease.
Critically, these benefits were consistent across the full spectrum of CKD severity — from milder to advanced kidney disease. Whether patients had eGFR above 60 or below 30, semaglutide provided similar protection. One standout finding: patients with the most severe kidney damage (UACR ≥2000 mg/g) had the largest mortality reduction — 53% lower death risk (HR 0.47). The primary outcome included kidney failure (≥50% eGFR decline, eGFR <15, dialysis, transplant) and death from kidney or cardiovascular causes.
Why it matters
This analysis answers a crucial clinical question: does semaglutide help even the sickest kidney patients? The answer is yes. Advanced CKD patients — who have the fewest treatment options and worst outcomes — benefit as much or more than those with milder disease. This is practice-changing evidence that supports using semaglutide broadly across CKD severity stages, not just in early disease. The 53% mortality reduction in the most severely affected subgroup is particularly striking.
The numbers in context
n=3,533 · Median follow-up 3.4 years · Primary outcome: HR 0.76 (0.66-0.88) · All-cause death: HR 0.80 (0.67-0.95) · Highest UACR subgroup death: HR 0.47 (0.31-0.70) · Mean eGFR 47 mL/min · Median UACR 568 mg/g · Consistent across all eGFR and UACR subgroups
How the study worked
FLOW was a double-blind, randomized, placebo-controlled trial comparing once-weekly subcutaneous semaglutide 1 mg to placebo in people with type 2 diabetes and CKD. This analysis stratified participants by baseline kidney function (eGFR subgroups from <30 to ≥60) and albumin leak severity (UACR subgroups from <100 to ≥2000 mg/g). The primary outcome was a composite of major kidney events and kidney/cardiovascular death. Interaction tests assessed whether treatment effects differed across subgroups.
Who was studied
3,533 adults with type 2 diabetes and chronic kidney disease across a wide range of disease severity
What this study cannot tell us
This is a subgroup analysis of the main FLOW trial, so individual subgroups have fewer participants and wider confidence intervals. The trial enrolled only people with type 2 diabetes and CKD, so results may not apply to CKD from other causes. The median eGFR of 47 means the very lowest eGFR ranges (<30) had relatively fewer participants. The striking mortality result in the highest UACR subgroup (HR 0.47) should be interpreted cautiously given the subgroup interaction p-value of 0.02.
How to read the evidence
This is a pre-specified subgroup analysis of a large, double-blind, randomized, placebo-controlled outcome trial (FLOW) published in a top nephrology journal. The large sample size, long follow-up, and hard clinical endpoints (kidney failure, death) represent the highest quality of clinical evidence. The main limitation is that subgroup analyses are hypothesis-generating, particularly the differential mortality benefit by UACR severity.
When this study was published
Published in 2026, this is the latest analysis from the FLOW trial — one of the most important kidney outcome trials in recent years. The findings are immediately relevant to current clinical practice and guideline development.
The bigger picture
The FLOW trial established semaglutide as the first GLP-1 agonist proven to protect kidneys in a dedicated kidney outcome trial. This subgroup analysis extends the findings to the full spectrum of CKD severity, which is critical for clinical guidelines. Combined with cardiovascular protection and weight loss benefits, semaglutide is emerging as one of the most broadly beneficial drugs in all of medicine — protecting the heart, kidneys, and metabolic health simultaneously.
Questions still open
- Should semaglutide now be considered standard of care for all type 2 diabetes patients with CKD, regardless of severity?
- Does semaglutide protect kidneys in non-diabetic CKD, or is the benefit specific to the diabetic kidney disease context?
- How does semaglutide's kidney protection compare to or complement SGLT2 inhibitors, the other major kidney-protective drug class?
Common questions
Can semaglutide help protect your kidneys from damage?
Is semaglutide still helpful if your kidneys are already badly damaged?
Read the original research
Kidney and Survival Outcomes with Semaglutide by Chronic Kidney Disease Severity in the FLOW Trial.
Clinical journal of the American Society of Nephrology : CJASN
Citation
Tuttle, Katherine R; Mann, Johannes F E; Mayrdorfer, Manuel M; Rayner, Brian; Pugliese, Giuseppe; Pratley, Richard E; Perkovic, Vlado; Mahaffey, Kenneth W; Kashihara, Naoki; Jeppesen, Ole K; Gumprecht, Janusz; Correa-Rotter, Ricardo; Cherney, David Z I; Bosch-Traberg, Heidrun; Arici, Mustafa; Rossing, Peter. (2026). Kidney and Survival Outcomes with Semaglutide by Chronic Kidney Disease Severity in the FLOW Trial.. Clinical journal of the American Society of Nephrology : CJASN. https://doi.org/10.2215/CJN.0000000974